Eric Murphy

Company: Kinnate Biopharma

Job title: Co-Founder and Chief Scientific Officer

Seminars:

Panel Discussion: Predicting Future Directions for NSCLC Therapeutic Development and Treatment 4:00 pm

How will future combinations, or novel therapeutic design (bispecifics etc), address acquired resistance to TKI treatments and improve patient outcomes? How will new, fast and accurate diagnostic technologies enable appropriate patient selection for future clinical investigations and increase the clinical utility of new approved therapies? What is on the horizon for targeted therapies for uncommon…Read more

day: Day Two

Targeting RAF Dimer Signaling in NSCLC Driven by BRAF Class II and III Mutations 10:50 am

Approved BRAF inhibitors such as vemurafenib, dabrafenib, and encorafenib are effective against cancers driven by V600 Class I mutations BRAF Class II alterations (e.g. G469A or BRAF fusion) are RASindependent and RAF-dimer dependent and represent a molecular subtype in NSCLC with unmet need BRAF Class III mutations represent a subtype with unmet need that are…Read more

day: Day Two